SCHEMBL23537370

SCHEMBL23537370

COc1nc2c(c3ccccc13)C(=O)CCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.49
▸ MAPT P10636 5/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.42
▸ CYP1A2 P05177 3/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ HPGD P15428 3/20 0.41
▸ HTT P42858 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ POLB P06746 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ BCHE P06276 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ BRD4 O60885 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29824468 1.00 ALDH1A1 (0.49) ALDH1A1MAPTNPSR1KDM4EHSD17B10
SCHEMBL12336195 0.78 ALDH1A1 (0.48) ALDH1A1MAPTKDM4EHSD17B10CYP1A2
SCHEMBL10871024 0.72 KDM4E (0.50) ALDH1A1MAPTNPSR1KDM4EHTT
SCHEMBL4495989 0.71 KDM4E (0.82) ALDH1A1KDM4EHSD17B10CYP1A2CYP2C19
SCHEMBL6434380 0.70 MAPT (0.46) ALDH1A1MAPTNPSR1KDM4EHSD17B10
Hydrochloric Acid SCHEMBL8984092 0.70 KDM4E (0.80) ALDH1A1MAPTKDM4EHSD17B10CYP1A2
SCHEMBL9875385 0.68 KDM4E (0.54) ALDH1A1MAPTNPSR1KDM4EHSD17B10
SCHEMBL8785150 0.67 ACHE (0.64) ALDH1A1MAPTKDM4EHSD17B10CYP1A2
SCHEMBL10848798 0.67 ACHE (0.67) ALDH1A1MAPTKDM4EHSD17B10CYP1A2
SCHEMBL8781744 0.66 KDM4E (0.55) ALDH1A1MAPTKDM4EHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230108906-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2023-04-06 — — US disclosed
EP-4076648-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-10-26 — — EP disclosed
CN-115087486-A Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof 爱彼特生物制药公司 2022-09-20 — — CN disclosed
WO-2021127356-A1 Substituted Bicyclic and Tricyclic Ureas and Amides, Analogues Thereof, and Methods Using Same ARBUTUS BIOPHARMA, INC. (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230108906-A1 SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME DDC, CDA, HMBS ALDH1A1 3407/4885MAPT 2508/4885NPSR1 4070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback